AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00561093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nepro
Description: Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
Study NCT00561093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: anti-inflammatory module (similar to Oxepa)
Description: Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
Study NCT00561093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill imitating pentoxiphylline
Description: Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
Study NCT00561093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill imitating pentoxiphylline
Description: Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
Study NCT00561093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo to imitate Nepro
Description: Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
Study NCT00561093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to imitate Nepro
Description: Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
Study NCT00561093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo to imitate anti-inflammatory module (similar to Oxepa)
Description: Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
Study NCT00561093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to imitate anti-inflammatory module (similar to Oxepa)
Description: Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
Study NCT00881452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CM-AT
Description: Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
Study NCT00881452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single unit dose powder of non-active substance administered 3 times per day for 90 days
Study NCT03039205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days
Study NCT03039205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days
Study NCT04372888 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: choice decision frame
Description: active choice for genetic testing
Study NCT04372888 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: opt-in decision frame
Description: gain frame for genetic testing
Study NCT04372888 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: opt-out decision frame
Description: loss frame for genetic testing
Study NCT04372888 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: enhanced choice (context) decision frame
Description: consequences of genetic testing
Study NCT04372888 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: enhanced choice (norms) decision frame
Description: social norms for genetic testing
Study NCT04372888 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: enhanced choice (affect) decision frame
Description: commitments for genetic testing
Study NCT00975884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Two intramuscular injections
Study NCT00047437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Training Program
Description: Exercise 30 minutes minimum three times per week.
Study NCT03448809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind My Mind
Description: An individual, modular and flexible cognitive and behavioural therapy
Study NCT03448809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU (Treatment as Usual)
Description: The children were offered anonymous counselling, supportive talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. A few were offered group-based CBT-programs for selected problems, but the access to manualized treatment was generally very restricted.
Study NCT02257827 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.~The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy.
Study NCT02257827 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.~The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy.
Study NCT04083066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab in combination with methotrexate, cytarabine and dexamethasone
Description: Rituximab 375mg/m2D0 is soluble in 0.9% NS concentration 1mg/ml, micro pump is pumped in 4h HD-methotrexate 3.5g/m2 D1 dissolved in 0.9% NS intravenous drip HD-cytarabine 1g/m2 Q12H D2-3 Dissolved in 250ml 5% GS intravenously~Dexamethasone 40mg D1-5 is dissolved in 100ml 5% GS intravenous drip (21 days is a cycle)
Study NCT00585039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xopenex
Description: will receive xopenex rather than albuterol to treat acute exacerbation
Study NCT04268771 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Arm A: DRL_RI
Description: Proposed rituximab biosimilar, 100mg or 500mg, concentrate for solution for infusion
Study NCT04268771 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm B: Rituxan®/Mabthera®
Description: Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion
Study NCT01636271 — intervention group
Intervention type: DRUG
Intervention: darapladib
Description: darapladib enteric coated tablets 160 mg
Study NCT03564496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS Administration during MRI
Description: All participants including healthy controls and MS patients will be given approximately 15 minutes of active tDCS during MRI. The simultaneous tDCS will be performed up to 2 mA dose intensity to determine CMRO2 changes from when the tDCS is on to when the tDCS is off. The stimulation consists of 15-min up to 2 mA tDCS using 5x5 cm electrode sponges with \~30s ramp-up and ramp-down periods.
Study NCT02634567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training (CWMT)
Description: The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
Study NCT02320838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5 KHz
Description: 5 KHz transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study NCT01636271 — intervention group
Intervention type: DRUG
Intervention: placebo
Description: placebo
Study NCT01700062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Description: Medium calorie ,Nonprotein calories 20 Kcal/Kg/day,Protein 1g/Kg,Fat emulsion 0.5 g/kg/day D1-D6 post OP standard calorie, Nonprotein calories 30 Kcal/Kg/day,Protein 1.5 g/Kg,Fat emulsion 50g/day D1-D6 post OP
Study NCT04637503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2, PSMA and CD276 CAR-T cells
Description: infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
Study NCT03831009 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction internal fixation (ORIF)
Description: Open fracture reduction followed by internal fixation using a plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
Study NCT03831009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Conservative treatment involves ankle protection with a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
Study NCT01120808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paper tape
Description: Paper tape assigned to each participant's randomly selected foot.
Study NCT05031312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inferior oblique weakening
Description: inferior oblique myectomy versus inferior oblique anterior nasal transposition in superior oblique palsy treatment
Study NCT03017404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection
Study NCT03017404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT03017404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT01914302 — intervention group
Intervention type: DEVICE
Intervention: Easy Touch Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances
Study NCT01914302 — intervention group
Intervention type: DEVICE
Intervention: Glucoject Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances
Study NCT01914302 — intervention group
Intervention type: DEVICE
Intervention: Microlet Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances
Study NCT01593670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: administered intravenous (IV), 10 mg/m\^2/day over 1 hour on days 1-5.
Study NCT01593670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 200 mg by mouth (PO) twice a day on days 6-15
Study NCT01593670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17
Study NCT01593670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural killer (NK) cells
Description: infusion intravenously (IV) over 15 to 60 minutes day 17
Study NCT00803608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueContour® Insole
Description: Novel designed insole
Study NCT00803608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Current standard of care insole
Description: Current Medicare approved A5513 insole
Study NCT03144661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB062079
Description: In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
Study NCT01768377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve block with Lidocain
Description: Lidocain 2% topical injection, 0.5 - 1 cc Lidocain 4% topical injection, 3 cc Lidocain 10% topical spray , total dose 50 mg
Study NCT01768377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 microgram/Kg BW IV
Study NCT01768377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 0.05 mg/kg BW IV infusion
Study NCT01768377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.05 mg/kg BW IV infusion
Study NCT01293916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spica casting
Description: single versus double leg spica casting
Study NCT01293916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spica casting
Description: single versus double leg spica casting
Study NCT02618291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Geriatric Evaluation (AGE tool)
Description: Yearly administration of the brief assessment tool (BAT). Once the presence of one or more geriatric syndromes is suspected using the brief assessment tool, a management strategy is proposed. It is divided in two distinct steps: 1) perform additional tests to confirm or exclude the diagnosis and 2) to propose specific management attitudes. All proposed attitudes are based on literature review and geriatrician expertise. The FP remains free to follow the proposed attitudes.
Study NCT02618291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit.
Study NCT03805412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEXCOM G6 RT-CGM
Description: CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.
Study NCT02974686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Study NCT02974686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid
Study NCT00879307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Use of quetiapine for 16 weeks in acute mania and depression
Study NCT00708461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight gain prevention
Description: 1. Changes in the food environment that increase the availability of healthy foods and beverages, reduce food and beverage portion sizes, reduce prices on healthy food items, and increase prices on less healthy food items.~2. Changes in the activity environment that increase cues and incentives for walking at work and at home, using stairs, and to increase exposure of employees to information about active recreational opportunities at work and at home.~3. Changes to the environment to increase cues and incentives for regular weight monitoring by providing scales at convenient locations.~4. Changes in the informational environment that increase frequency of exposure of the employee population to accurate information about healthy food and activity choices.
Study NCT03102996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nephrotrans
Description: Sodium hydrogen carbonate, ATC-Code: A02AH
Study NCT03102996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsules without active substance.
Study NCT04208451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alixir 400 Protect
Description: During 30 days all patients take every day 30ml of Alixir 400 protect
Study NCT01239810 — intervention group
Intervention type: DRUG
Intervention: Hyaluronic Acid
Description: Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks
Study NCT02320838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study NCT02320838 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study NCT02296788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
Study NCT02284295 — intervention group
Intervention type: OTHER
Intervention: exposure to respirable silica dust
Description: History of exposure to respirable silica dust due to job
Study NCT02284295 — intervention group
Intervention type: OTHER
Intervention: exposure to aromatic hydrocarbons
Description: history of exposure to aromatic hydrocarbons due to job
Study NCT06517602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation of Moringa oleifera leaf powder
Description: Women in the experimental group were asked to consistently take the prescribed oral hypoglycemic therapy and to maintain their lifestyle and eating habits. In addition, for the duration of the study (3 months), the experimental group was provided with 10 g of Moringa oleifera leaf powder daily to be consumed with main meals.
Study NCT02453867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced immunosuppression
Description: Stop steroids at month 3 Stop mycophenolate at month 6 continue tacrolimus once daily (Advagraf, trough levels > 5ng/ml) Stop mycophenolate at month 6
Study NCT02453867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is used in both the acitve comparator arm and the interventional arm
Study NCT02453867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus is used in both the acitve comparator arm and the interventional arm
Study NCT02453867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate
Description: Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm
Study NCT02453867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate
Description: Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm
Study NCT02453867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
Study NCT00998582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Description: Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
Study NCT00998582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
Study NCT02898064 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: thoracolumbosacral orthosis or cervicothoracolumbar orthosis
Description: An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used.
Study NCT02898064 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care
Study NCT00430638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide, if necessary
Description: olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
Study NCT00430638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets administered for once daily for 12 weeks